Related Subjects:
|Status Epilepticus (Epilepsy)
|Coma management
|Lorazepam
|Phenytoin
|Levetiracetam
|Epilepsy - General Management
|First Seizure
|Epilepsy in Pregnancy
|Febrile seizures
⚠️ Important: Carbamazepine is associated with severe cutaneous adverse reactions (SCAR), including Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), especially in patients of Han Chinese or Thai origin carrying the HLA-B*1502 allele. Genetic screening is recommended in high-risk groups.
It may also worsen absence and myoclonic seizures.
📖 About
- Carbamazepine is an anticonvulsant and mood stabiliser.
- It is also the drug of choice in the UK for trigeminal neuralgia.
- It is a potent inducer of cytochrome P450 enzymes, reducing the efficacy of many co-administered drugs.
- Always check the BNF for up-to-date prescribing guidance.
⚙️ Mode of Action
- Blocks voltage-gated sodium channels in neuronal membranes → stabilises hyperexcited nerve tissue.
- Reduces repetitive neuronal firing and prevents seizure propagation.
- Weak effect on calcium channels and neurotransmitter modulation.
- Potent hepatic enzyme inducer (CYP3A4).
🩺 Indications & Typical Dose
- Epilepsy: focal seizures (with or without secondary generalisation), generalised tonic–clonic seizures. Avoid in absence/myoclonic epilepsy.
- Trigeminal neuralgia: first-line drug in the UK.
- Bipolar disorder: sometimes used as a mood stabiliser (less common than lithium or valproate).
💊 Dosing – Carbamazepine (PO, UK practice; verify with BNF/datasheet)
| Indication |
Details |
| ⚡ Epilepsy |
• Start: 100–200 mg 1–2 times daily
• Titrate every 1–2 weeks
• Maintenance: 400–800 mg BD
• Max: ~1600 mg/day
|
| 💥 Trigeminal Neuralgia |
• Start: 100 mg 1–2 times daily
• Titrate to lowest effective dose (typically 200 mg TDS)
• Max: 1200 mg/day
|
| 🧠 Bipolar Disorder (specialist use) |
• Start: 200 mg OD
• Increase gradually
• Maintenance: 400–600 mg/day
|
🧪 Monitoring
- Baseline: FBC, U&E (esp. sodium), LFTs, BMI, pregnancy test if appropriate.
- During therapy: FBC, U&E, LFTs periodically (risk of agranulocytosis, hyponatraemia, hepatotoxicity).
- Drug levels: not routine; check if poor control, toxicity suspected, or adherence concerns. Therapeutic range: 4–12 mg/L (20–50 µmol/L).
- Toxicity: usually >12 mg/L (50 µmol/L) → ataxia, diplopia, drowsiness.
⚠️ Side Effects
- Common: nausea, dizziness, drowsiness, diplopia, ataxia, headache, blurred vision, rash.
- Serious: aplastic anaemia, agranulocytosis, SIADH → hyponatraemia (esp. elderly), hepatic dysfunction, pancreatitis.
- Skin reactions: urticaria, severe hypersensitivity (SJS/TEN) — especially in Asians with HLA-B*1502 allele.
- Pregnancy: teratogenic (↑ risk of neural tube defects, craniofacial anomalies).
⚠️ Cautions
- Ethnicity: screen Han Chinese and Thai patients for HLA-B*1502 before initiation.
- CNS depression may impair driving or machine operation.
- Use caution in elderly (risk of SIADH/hyponatraemia).
- Gradual withdrawal required to avoid seizure rebound.
🔄 Interactions
- Enzyme induction: reduces efficacy of oral contraceptives, anticoagulants (warfarin), ciclosporin, antivirals, many others.
- Inhibitors (↑ carbamazepine levels): macrolides (erythromycin, clarithromycin), diltiazem, verapamil, azole antifungals.
- Other AEDs: complex bidirectional interactions with phenytoin, valproate, lamotrigine.
🚫 Contraindications
- Worsens absence and myoclonic epilepsy.
- History of bone marrow suppression.
- Concomitant use with MAOIs.
- Cardiac conduction disorders (e.g. AV block).
- Acute porphyria.
📚 References